CGEM

Cullinan Therapeutics, Inc. - Common Stock (CGEM)

About Cullinan Therapeutics, Inc. - Common Stock (CGEM)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Details

Daily high

$21.84

Daily low

$21.29

Price at open

$21.44

52 Week High

$23.19

52 Week Low

$5.68

Market cap

1.4B

Dividend yield

Volume

202,614

Avg. volume

926,091

P/E ratio

-6.29

Cullinan Therapeutics, Inc. - Common Stock News